Editors' picks from other sources

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental HIV treatments news

Show

From To
Lipodystrophy
Health Canada rejects tesamorelin for lipodystrophy

After consideration of the NDS, Health Canada decided that the risks of tesamorelin outweighed its benefits under the proposed conditions of use.

Published
13 March 2013
From
Theratechnologies press release
Microbicides
Bee Venom Destroys HIV And Spares Surrounding Cells

Nanoparticles containing bee venom toxin melittin can destroy human immunodeficiency virus (HIV) while at the same time leaving surrounding cells unharmed, scientists from Washington University School of Medicine reported in the March 2013 issue of Antiviral Therapy.

Published
10 March 2013
From
HIV / AIDS News From Medical News Today
Finance and funding
Funding Scientific Innovation: Global Investments in HIV Treatment Research and Development in 2010 and 2011

The latest report found US$2.6 billion was invested in HIV treatment R&D in 2011. Data from 41 public, private, and philanthropic donors reveal a 12% increase in funding from the baseline year of 2009, with the majority of funding targeted at research for new medications.

Published
07 March 2013
From
Treatment Action Group
Pharmaceutical industry
GSK wins priority status for new HIV drug in US

U.S. regulators gave priority review status to an experimental GlaxoSmithKline drug for HIV/AIDS, which industry analysts view as a possible multibillion-dollar-a-year seller.

Published
18 February 2013
From
Reuters
How HIV works
Newly identified natural protein blocks HIV, other deadly viruses

A team of UCLA-led researchers has identified a protein with broad virus-fighting properties that potentially could be used as a weapon against deadly human pathogenic viruses such as HIV, Ebola, Rift Valley Fever, Nipah and others designated "priority pathogens" for national biosecurity purposes by the National Institute of Allergy and Infectious Disease.

Published
12 February 2013
From
UCLA press release
New and experimental HIV treatments
ViiV announces halt to lersivirine development

On February 5, 2013, ViiV Healthcare announced that the company has decided to stop the development program investigating its experimental non-nucleoside reverse transcriptase inhibitor (NNRTI) lersivirine.

Published
07 February 2013
From
HIVandHepatitis.com
New and experimental HIV treatments
Innovative HIV Gene Therapy Study Soon to Start Enrollment

Calimmune, a small biotechnology company, has been given the go-ahead by the U.S. Food and Drug Administration to start enrolling HIV-infected people in a first-of-its-kind gene therapy study that will modify two HIV attachment sites in CD4+ cells.

Published
06 February 2013
From
TheBody.com
New and experimental HIV treatments
Suboptimal Suppression with Maraviroc plus a Boosted Protease Inhibitor?

Until larger studies are done, such regimens are probably best avoided.

Published
05 February 2013
From
Journal Watch
New and experimental HIV treatments
Gilead Initiates Phase 3 Clinical Program for Tenofovir Alafenamide, a Novel Low-Dose Prodrug for the Treatment of HIV

The Phase 3 studies will examine a once-daily single tablet regimen of TAF 10 mg/elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg compared to Gilead’s Stribild®(elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) among patients new to HIV therapy.

Published
25 January 2013
From
Gilead press release
Pharmaceutical industry
Gilead petitions FDA over its Stribild AIDS med

In a challenge to FDA decisionmaking that will be closely watched by the pharmaceutical industry, Gilead Sciences has asked the agency to grant five years of exclusivity to its recently approved Stribild AIDS medication.

Published
25 January 2013
From
Pharmalot
← First12345...26Next →

Filter by country